Noor Zaswiza Mohamad, Smith Alesha J, Smith Simon S, Nissen Lisa M
School of Pharmacy, Pharmacy Australia Centre of Excellence (PACE), The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD 4102, Australia.
BMC Health Serv Res. 2014 Feb 18;14:74. doi: 10.1186/1472-6963-14-74.
Sleep disorders are very common in the community and are estimated to affect up to 45% of the world's population. Pharmacists are in a position to give advice and provide appropriate services to individuals who are unable to easily access medical care. The purpose of this study is to develop an intervention to improve the management of sleep disorders in the community. The aims are- (1) to evaluate the effectiveness of a community pharmacy-based intervention in managing sleep disorders, (2) to evaluate the role of actigraph as an objective measure in monitoring certain sleep disorders and (3) to evaluate the extended role of community pharmacists in managing sleep disorders. This intervention is developed to monitor individuals undergoing treatment and overcome the difficulties in validating self-reported feedback.
METHOD/DESIGN: This is a community-based intervention, prospective, controlled trial, with one intervention group and one control group, comparing individuals receiving a structured intervention with those receiving usual care for sleep-related disorders at community pharmacies.
This study will demonstrate the utilisation and efficacy of community pharmacy-based intervention to manage sleep disorders in the community, and will assess the possibility of implementing this intervention into the community pharmacy workflow.
Australian New Zealand Clinical Trial Registry: ACTRN12612000825853.
睡眠障碍在社区中非常常见，据估计影响着全球多达45%的人口。药剂师能够为那些难以获得医疗服务的个人提供建议并提供适当的服务。本研究的目的是开发一种干预措施，以改善社区中睡眠障碍的管理。目标如下：（1）评估基于社区药房的干预措施在管理睡眠障碍方面的有效性；（2）评估活动记录仪作为监测某些睡眠障碍的客观指标的作用；（3）评估社区药剂师在管理睡眠障碍方面的扩展作用。开发此干预措施是为了监测接受治疗的个体，并克服验证自我报告反馈的困难。
方法/设计：这是一项基于社区的干预性前瞻性对照试验，设有一个干预组和一个对照组，比较在社区药房接受结构化干预的个体与接受睡眠相关疾病常规护理的个体。
本研究将证明基于社区药房的干预措施在社区管理睡眠障碍中的应用和疗效，并将评估将此干预措施纳入社区药房工作流程的可能性。
澳大利亚新西兰临床试验注册中心：ACTRN12612000825853。
